Daily Respiratory Research Analysis
Analyzed 69 papers and selected 3 impactful papers.
Summary
Today's most impactful respiratory research spans a potentially curable metabolic cause of pediatric pulmonary hypertension, sex-specific machine-learning prediction of COPD, and a randomized comparison of ciprofol versus propofol for respiratory safety during procedural sedation. Collectively, these studies emphasize precision diagnosis, biologically informed risk prediction, and safer respiratory care.
Research Themes
- Precision diagnosis of reversible pulmonary hypertension
- Sex-specific artificial intelligence for COPD prediction
- Improving respiratory safety during procedural sedation
Selected Articles
1. Misdiagnosed as Idiopathic PAH: Methylmalonic Acidemia as a Reversible Cause of Pediatric Pulmonary Hypertension.
This 10-year multicenter retrospective study compared 13 children with methylmalonic acidemia-associated pulmonary hypertension with 113 children with idiopathic or hereditary pulmonary arterial hypertension. MMA-associated disease accounted for 2.7% of pediatric pulmonary hypertension, was characterized by younger age and multisystem abnormalities, and achieved complete clinical and hemodynamic remission in all patients after metabolic therapy and short-term pulmonary vasodilators, with no relapse during a median 7-year follow-up.
Impact: The study identifies a rare but highly treatable cause of pediatric pulmonary hypertension that can be mistaken for idiopathic disease. Recognition may convert a chronic, high-risk diagnosis into a potentially curable metabolic disorder.
Clinical Implications: Children with unexplained pulmonary hypertension should undergo metabolic evaluation when growth failure, malnutrition, recurrent pneumonia, hematuria, proteinuria, or markedly elevated homocysteine is present. Routine total homocysteine testing may help identify MMA-associated disease before irreversible cardiopulmonary damage develops.
Key Findings
- Methylmalonic acidemia-associated pulmonary hypertension accounted for 2.7% of pediatric pulmonary hypertension cases in the study population.
- Compared with idiopathic or hereditary pulmonary arterial hypertension, affected children were younger and more frequently had growth failure, malnutrition, recurrent pneumonia, microscopic hematuria, and proteinuria.
- All patients achieved complete clinical and hemodynamic remission within one year after metabolic therapy and short-term pulmonary vasodilators, with no relapse during a median 7-year follow-up.
Methodological Strengths
- Multicenter comparison over a 10-year period with an idiopathic or hereditary pulmonary arterial hypertension comparator group.
- Long-term follow-up and assessment of both clinical and hemodynamic remission.
Limitations
- The MMA-associated group was small, comprising only 13 patients, which limits precision and generalizability.
- The retrospective design may introduce referral, selection, and treatment-related biases, and the findings require validation in other populations.
Future Directions: Prospective international registries should determine the true prevalence of MMA-associated pulmonary hypertension, establish standardized metabolic screening pathways, and compare the necessity and duration of pulmonary vasodilator therapy after metabolic correction.
BACKGROUND: Methylmalonic acidemia (MMA)-induced pulmonary hypertension (PH) is a rare but treatable cause of pediatric PH, often misdiagnosed as idiopathic pulmonary arterial hypertension (IPAH). METHODS: We conducted a 10-year, multicenter retrospective study of children with clinically unexplained PH. Thirteen patients with MMA-PH were compared to 113 with idiopathic or hereditary PAH (IPAH/HPAH) regarding clinical features, hemodynamics, and outcomes. RESULTS: MMA-PH accounted for 2.7% of pediatric PH cases. Patients presented younger (7±4 vs. 11±5 years, p=0.008) and exhibited higher rates of growth failure (84.6% vs. 15.9%, p<0.001), anorexia/malnutrition (76.9% vs. 14.2%, p<0.001), recurrent pneumonia (46.2% vs. 13.3%, p=0.003), microscopic hematuria (84.6% vs. 1.8%, p<0.001), and proteinuria (31% vs. 4.4%, p=0.007) than IPAH/HPAH.
2. Sex-specific machine learning improves prediction of incident and prevalent COPD.
Using 1,283 participants from CanCOLD and 1,840 from SPIROMICS, this study compared combined-sex, male-only, and female-only CT-based machine-learning models for incident and prevalent COPD. Female-specific models consistently outperformed male-only and combined-sex models in internal and external testing, while identifying different disease-relevant imaging features by sex.
Impact: The study provides externally validated evidence that sex-neutral prediction models can obscure clinically relevant biological differences. Sex-specific modeling could improve early COPD detection, risk stratification, and selection of patients for preventive or disease-modifying strategies.
Clinical Implications: Future COPD screening and risk-prediction tools may benefit from sex-specific algorithms, particularly for women in whom conventional approaches may underrecognize disease. Clinical implementation will require prospective validation, calibration across populations, and assessment of whether improved prediction changes outcomes.
Key Findings
- The study included 1,283 CanCOLD participants and 1,840 SPIROMICS participants for external testing.
- For incident COPD, the female-only model achieved AUCs of 0.86 internally and 0.83 externally, outperforming the male-only and combined-sex models.
- For prevalent COPD, the female-only model achieved AUCs of 0.84 in both internal and external testing, while female and male models selected different imaging features.
Methodological Strengths
- Large, well-characterized cohort with independent external validation in a second COPD study population.
- Direct comparison of combined-sex and sex-specific models using multiple CT-derived parenchymal and airway features.
Limitations
- The observational cohort design demonstrates predictive performance but does not establish that model-guided intervention improves clinical outcomes.
- The models may require recalibration before use in populations with different demographics, smoking patterns, imaging protocols, or disease prevalence.
Future Directions: Prospective implementation studies should evaluate whether sex-specific COPD prediction changes referral for spirometry, smoking-cessation interventions, exacerbation prevention, or early pharmacologic treatment, while addressing fairness and calibration across diverse populations.
BACKGROUND: Computed tomography imaging with machine learning can predict incident and prevalent chronic obstructive pulmonary disease (COPD), however, it is unknown if sex-specific models improve performance. RESEARCH QUESTION: Do sex-specific machine learning models using computed tomography (CT) derived disease features improve prediction of incident and prevalent chronic obstructive pulmonary disease (COPD) and identify sex-specific predictors? STUDY DESIGN AND METHODS: Canadian Cohort Obstructive Lung Disease (CanCOLD) study participants underwent baseline CT imaging, and spirometry at baseline/follow-up. Models predicted incident and prevalent COPD using demographics and CT features (lung density/texture/shape, airway shape) for the combined-sex, male-only, and female-only datasets, and externally tested in Subpopulations and Intermediate Outcome Measures in COPD (SPIROMICS). Performance was evaluated using area under the receiver operating characteristic curve (AUC). RESULTS: 1283 CanCOLD and 1840 SPIROMICS participants were included.
3. Comparison of Incidence of Respiratory Depression Between Ciprofol versus Propofol for Procedural Sedation During First-Trimester Surgical Abortion: A Randomized Controlled Trial.
In this single-center, assessor-blinded randomized controlled trial, 226 patients undergoing first-trimester surgical abortion received ciprofol or propofol, both with alfentanil. Respiratory depression occurred less frequently with ciprofol than propofol, at 9.7% versus 20.4%, while procedural sedation efficacy was comparable.
Impact: Respiratory depression is a clinically important complication of procedural sedation, and this randomized comparison suggests a potentially safer alternative to propofol. The finding is directly relevant to anesthetic selection but requires confirmation in broader settings and patient populations.
Clinical Implications: Ciprofol may be considered as an alternative sedative when minimizing respiratory depression is a priority, particularly in short outpatient procedures. Adoption should await larger multicenter trials, detailed safety comparisons, and evidence in patients with respiratory or cardiovascular comorbidities.
Key Findings
- A total of 226 patients were randomized equally to ciprofol and propofol groups, with alfentanil administered in both groups.
- Respiratory depression occurred in 9.7% of patients receiving ciprofol compared with 20.4% receiving propofol.
- Ciprofol provided comparable procedural sedation efficacy while being associated with fewer perioperative adverse events in the reported study population.
Methodological Strengths
- Randomized controlled design with assessor blinding and equal allocation between treatment groups.
- The study compared agents under a standardized alfentanil-containing sedation regimen and used respiratory depression as the primary safety outcome.
Limitations
- The trial was conducted at a single center and included a specific population undergoing first-trimester surgical abortion, limiting generalizability.
- The sample size was modest, and the abstract does not establish comparative efficacy for rare serious cardiopulmonary adverse events or longer-term outcomes.
Future Directions: Larger multicenter trials should compare ciprofol and propofol across diverse procedures, include patients at increased risk of respiratory compromise, evaluate dose-response relationships, and assess recovery time, airway interventions, and cost-effectiveness.
BACKGROUND: Respiratory depression remains a major safety concern during propofol-based sedation for surgical abortion. Ciprofol is a novel intravenous sedative-hypnotic agent with pharmacological properties similar to propofol and a potentially improved safety profile. This randomized controlled trial aimed to compare the incidence of respiratory depression of ciprofol versus propofol, both combined with alfentanil, for procedural sedation in patients undergoing surgical abortion. METHODS: In this single-center, assessor-blinded, randomized controlled trial, 234 patients scheduled for surgical abortion under intravenous anesthesia were assessed for eligibility, and 226 were randomly assigned to receive either ciprofol (0.4 mg/kg; n=113) or propofol (2.0 mg/kg; n=113). Alfentanil (7.5 μg/kg) was administered intravenously as part of anesthesia induction in all patients. The primary outcome was the incidence of respiratory depression.